Optimvia and Ginkgo Bioworks Ink Deal to Manufacture Biosynthetic Heparin
Ginkgo Bioworks forms partnerships to improve manufacturing processes of key medicines. Heparin prevents blood clots and is classified as an essential medicine by the WHO. Producing non-animal derived heparin is intended to be proof-of-principle for Optimvia's platform technology for synthesizing sulfated glycans. Enabling enzymatic manufacturing could create supply chain diversity and reduce or eliminate the need for high volume heparin extraction from porcine intestines.
Source: genengnews.com
